Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vasc...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-05-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-of-edoxaban-versus-rivaroxaban-for-stroke-preventio-peer-reviewed-article-CEOR |
| _version_ | 1828531914899718144 |
|---|---|
| author | Miller JD Ye X Lenhart GM Farr AM Tran OV Kwong WJ Magnuson EA Weintraub WS |
| author_facet | Miller JD Ye X Lenhart GM Farr AM Tran OV Kwong WJ Magnuson EA Weintraub WS |
| author_sort | Miller JD |
| collection | DOAJ |
| description | Jeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vascular Health, Christiana Care Health System, Newark, DE, USABackground: Understanding the value of new anticoagulation therapies compared with existing therapies is of paramount importance in today’s cost-conscious and efficiency-driven health care environment. Edoxaban and rivaroxaban for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with CHADS2 scores ≥2 have been evaluated in pivotal trials versus warfarin. The relative value of edoxaban versus rivaroxaban would be of interest to health care stakeholders and patients who prefer a once-daily treatment option for long-term stroke prevention in NVAF.Objective: To evaluate the relative cost-effectiveness of two once-daily regimens of novel oral anticoagulation therapy – edoxaban (60 mg/30 mg dose-reduced) versus rivaroxaban (20 mg/15 mg dose-reduced) – for stroke prevention in NVAF patients from a US health-plan perspective.Materials and methods: A Markov model simulated lifetime risk and treatment of stroke, systemic embolism, major bleeding, clinically relevant nonmajor bleeding, myocardial infarction, and death in NVAF patients treated with edoxaban or rivaroxaban. Efficacy and safety data were derived from a network meta-analysis that utilized data from patients enrolled in ENGAGE AF-TIMI 48 and ROCKET-AF. Health care cost and utility data were obtained from published sources. Incremental cost-effectiveness ratios of $150,000 per quality-adjusted life year (QALY) gained were used as thresholds for “highly cost-effective”, “cost-effective”, and “not cost-effective” treatment options, respectively, as per American Heart Association/American College of Cardiology guidelines.Results: Edoxaban was dominant relative to rivaroxaban, such that it was associated with lower total health care costs and better effectiveness in terms of QALYs in the base-case analysis. Results were supported by probabilistic sensitivity analyses that showed edoxaban as either dominant or a highly cost-effective alternative (incremental cost-effectiveness ratio <$50,000) to rivaroxaban in 88.4% of 10,000 simulations.Conclusion: Results of this study showed that the once-daily edoxaban (60 mg/30 mg dose-reduced) regimen is a cost-saving or highly cost-effective treatment relative to rivaroxaban (20 mg/15 mg dose-reduced) for stroke prevention in NVAF patients with CHADS2 ≥2.Keywords: edoxaban, rivaroxaban, cost-effectiveness, nonvalvular atrial fibrillation, oral anticoagulation, stroke, NOAC, SPAF, economic model, economic analysis |
| first_indexed | 2024-12-11T22:44:44Z |
| format | Article |
| id | doaj.art-8fbc383ead0f4907a4d9dc7953ea81e0 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-11T22:44:44Z |
| publishDate | 2016-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-8fbc383ead0f4907a4d9dc7953ea81e02022-12-22T00:47:39ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812016-05-012016Issue 121522627048Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the USMiller JDYe XLenhart GMFarr AMTran OVKwong WJMagnuson EAWeintraub WSJeffrey D Miller,1 Xin Ye,2 Gregory M Lenhart,1 Amanda M Farr,1 Oth V Tran,1 W Jackie Kwong,2 Elizabeth A Magnuson,3 William S Weintraub41Truven Health Analytics Inc, Cambridge, MA, 2Daiichi Sankyo Inc, Parsippany, NJ, 3St Luke Mid-America Heart Institute, Kansas City, MO, 4Center for Heart and Vascular Health, Christiana Care Health System, Newark, DE, USABackground: Understanding the value of new anticoagulation therapies compared with existing therapies is of paramount importance in today’s cost-conscious and efficiency-driven health care environment. Edoxaban and rivaroxaban for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with CHADS2 scores ≥2 have been evaluated in pivotal trials versus warfarin. The relative value of edoxaban versus rivaroxaban would be of interest to health care stakeholders and patients who prefer a once-daily treatment option for long-term stroke prevention in NVAF.Objective: To evaluate the relative cost-effectiveness of two once-daily regimens of novel oral anticoagulation therapy – edoxaban (60 mg/30 mg dose-reduced) versus rivaroxaban (20 mg/15 mg dose-reduced) – for stroke prevention in NVAF patients from a US health-plan perspective.Materials and methods: A Markov model simulated lifetime risk and treatment of stroke, systemic embolism, major bleeding, clinically relevant nonmajor bleeding, myocardial infarction, and death in NVAF patients treated with edoxaban or rivaroxaban. Efficacy and safety data were derived from a network meta-analysis that utilized data from patients enrolled in ENGAGE AF-TIMI 48 and ROCKET-AF. Health care cost and utility data were obtained from published sources. Incremental cost-effectiveness ratios of $150,000 per quality-adjusted life year (QALY) gained were used as thresholds for “highly cost-effective”, “cost-effective”, and “not cost-effective” treatment options, respectively, as per American Heart Association/American College of Cardiology guidelines.Results: Edoxaban was dominant relative to rivaroxaban, such that it was associated with lower total health care costs and better effectiveness in terms of QALYs in the base-case analysis. Results were supported by probabilistic sensitivity analyses that showed edoxaban as either dominant or a highly cost-effective alternative (incremental cost-effectiveness ratio <$50,000) to rivaroxaban in 88.4% of 10,000 simulations.Conclusion: Results of this study showed that the once-daily edoxaban (60 mg/30 mg dose-reduced) regimen is a cost-saving or highly cost-effective treatment relative to rivaroxaban (20 mg/15 mg dose-reduced) for stroke prevention in NVAF patients with CHADS2 ≥2.Keywords: edoxaban, rivaroxaban, cost-effectiveness, nonvalvular atrial fibrillation, oral anticoagulation, stroke, NOAC, SPAF, economic model, economic analysishttps://www.dovepress.com/cost-effectiveness-of-edoxaban-versus-rivaroxaban-for-stroke-preventio-peer-reviewed-article-CEORedoxabanrivaroxabancost-effectivenessnon-valvular atrial fibrillationoral anticoagulationstroke |
| spellingShingle | Miller JD Ye X Lenhart GM Farr AM Tran OV Kwong WJ Magnuson EA Weintraub WS Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US ClinicoEconomics and Outcomes Research edoxaban rivaroxaban cost-effectiveness non-valvular atrial fibrillation oral anticoagulation stroke |
| title | Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US |
| title_full | Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US |
| title_fullStr | Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US |
| title_full_unstemmed | Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US |
| title_short | Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US |
| title_sort | cost effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation nvaf in the us |
| topic | edoxaban rivaroxaban cost-effectiveness non-valvular atrial fibrillation oral anticoagulation stroke |
| url | https://www.dovepress.com/cost-effectiveness-of-edoxaban-versus-rivaroxaban-for-stroke-preventio-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT millerjd costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT yex costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT lenhartgm costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT farram costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT tranov costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT kwongwj costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT magnusonea costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus AT weintraubws costeffectivenessofedoxabanversusrivaroxabanforstrokepreventioninpatientswithnonvalvularatrialfibrillationnvafintheus |